News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Bolder BioTechnology, Inc. Receives National Institutes of Health (NIH) Grant For Preclinical Development Of Proprietary Erythropoiesis-Stimulating Protein

10/19/2005 5:12:16 PM

WHEAT RIDGE, Colo., Jan. 13 /PRNewswire/ -- Bolder BioTechnology, Inc. today announced that it has been awarded a $500,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health. The two-year grant will be used to optimize the manufacturing process and perform preclinical toxicology and pharmacology studies of the company's proprietary erythropoiesis-stimulating protein, which is being developed as a potential treatment for anemia associated with chronic kidney disease and chemotherapy. Receipt of the entire grant award is contingent upon the achievement of certain research milestones.

The SBIR program is a peer-reviewed grant program that provides research support to small businesses to discover and develop innovative biomedical products for the treatment of serious unmet medical needs. Companies that successfully meet the goals of the Phase I grant are eligible to apply for additional Phase II grant support to continue their product development efforts.

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary, long-acting human protein pharmaceuticals for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. For additional information about Bolder BioTechnology, Inc., please visit our web site at

Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward- looking statements made by the Company. These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.

Bolder BioTechnology, Inc.

CONTACT: Joe Cox, Ph.D., President of Bolder BioTechnology, Inc.,+1-303-420-4420, ext. 101

Read at

comments powered by Disqus